Prostate-cancer mortality at 11 years of follow-up. - Test2 - elhamkhani - TriplyDB

Prostate-cancer mortality at 11 years of follow-up.

Prostate-cancer mortality at 11 years of follow-up.

http://www.wikidata.org/entity/Q34261229

about

Screening for prostate cancer Adverse effects of testosterone replacement therapy: an update on the evidence and controversy Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion.Clinical validity and utility of genetic risk scores in prostate cancer Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review Current status of active surveillance in prostate cancer Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis The many ways to make a luminal cell and a prostate cancer cell Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer Emerging PSA-based tests to improve screening Overdiagnosis and overtreatment of prostate cancer Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles Computer aided-diagnosis of prostate cancer on multiparametric MRI: a technical review of current research Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN Prostate cancer: ESMO Consensus Conference Guidelines 2012 Prostate cancer treatment: the times they are a' changin'Genetically engineered mouse models of prostate cancer Prostate cancer screening in Brazil: should it be done or not?Association between insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia Differential Predictive Roles of A- and B-Type Nuclear Lamins in Prostate Cancer Progression A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer Prostate cancer epigenetics and its clinical implications The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Is the false-positive rate in mammography in North America too high?Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare.A Community Jury on PSA screening: what do well-informed men want the government to do about prostate cancer screening--a qualitative analysis Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.Defining the optimal approach to the patient with postradiation prostate-specific antigen recurrence using outcome data from a prospective randomized trial.[Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.Minimization of errors in biexponential T2 measurements of the prostate.Patterns of care and treatment trends for Canadian men with localized low-risk prostate cancer: an analysis of provincial cancer registry data Prostate cancer screening: a complicated puzzle, explanation needed

P2860

Q24201690-EDDD3EF5-DAF9-4120-A030-EF4AF705AC99 Q24564836-F4E59199-46EF-422E-9663-BAA50051DBE7 Q24620320-94D6945A-BBF5-4914-B79C-53DB96838F62 Q26746219-41210713-A74B-48B6-AF23-EDDB9A6731D7 Q26748872-DBC935D5-C974-4EF0-877D-3BA71D58450E Q26748873-0E5A4EF1-F30E-40B8-B221-E5037AD9670F Q26766307-EBD323C9-4899-4DB2-8FBA-46F8D54245FF Q26773634-6992A8DF-A86E-498A-987B-7742828D7812 Q26775766-E0B562AB-1657-46BE-ABF0-625781228E76 Q26781089-AD581FCA-56BE-4C02-B2FB-E17A1721DC00 Q26781093-80D8D18A-0EBD-4D84-AAEA-9C0119AAF0C9 Q26797386-E8BAFFAF-6DD7-4C7F-B4FE-F4DDB905C979 Q26824913-7CD8038C-D859-4811-BEC2-18E539E9DDF7 Q26828563-F982CD50-509A-4562-ABF0-AB817DB36CB1 Q26859596-C8DC62D4-6C9C-4BDD-A80F-68634D9E554B Q26865810-3A911A72-9E88-4ECE-A735-373D04725AEA Q27004458-C3076D0F-AE9A-40ED-8186-C674BDEE98DE Q27005677-438DD8E2-890D-44EC-96F3-E90291B30100 Q27022847-231D1F56-A930-4D28-A29F-EB26F9FAEA43 Q27025607-7C28EC63-CD8D-4365-BEEA-9BD0815CFAEE Q27026768-E291AF39-8FEF-45BC-B09B-B5C07A0990B4 Q28068688-1B685A5F-2832-4E3B-B636-8EA5CF88BCD8 Q28077769-AF9B1F75-8137-499F-9ED5-CF8E6DFC960F Q28085419-B234BB9A-4EE7-4635-9F47-33E1AED6866A Q28550287-1760FC47-F630-4ED7-805B-41DE72A94093 Q28652628-7F7F4BD4-25C0-4E61-A5B2-0A22718BEFA4 Q28829460-942AEAF8-9E0C-4CF3-A3B0-1FA8D70C5C23 Q30239973-C34C74E7-0F6B-4A24-A0F8-B9A166D55857 Q30250289-29E3DCCB-43BC-4CF6-A48B-D93F08C944DE Q30395328-D8987FBF-F0B1-4803-8742-251C7AD111DA Q30573273-769E062E-2362-453B-B865-DCEE0BF3DEAC Q30577573-B21302AD-0D13-4E90-9590-ABCB8172360E Q30597063-7D002997-4F73-4BDC-BFBF-A54C6593623A Q30612397-59756CA3-AC84-41CF-A4F3-4DEFCA57B67F Q30651467-53829082-041A-4F7D-BFE9-4EEADBA95C6F Q30793372-FD73C45E-6295-4219-AD80-948F775DFAC6 Q30878080-D6F3BA3E-B382-4386-9816-2D308FCF4811 Q30897579-5E41DCF1-2198-483B-B020-5A5FD22B3F55 Q31056768-EDF4A892-A92C-49BD-AE15-18849C035D63 Q33356114-A1FC9A3C-7089-450C-A06D-A663CB5653B2

P2860

Prostate-cancer mortality at 11 years of follow-up.

http://www.wikidata.org/entity/Q34261229

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Prostate-cancer mortality at 11 years of follow-up.

@ast

Prostate-cancer mortality at 11 years of follow-up.

@en

Prostate-cancer mortality at 11 years of follow-up.

@nl

type

label

Prostate-cancer mortality at 11 years of follow-up.

@ast

Prostate-cancer mortality at 11 years of follow-up.

@en

Prostate-cancer mortality at 11 years of follow-up.

@nl

prefLabel

Prostate-cancer mortality at 11 years of follow-up.

@ast

Prostate-cancer mortality at 11 years of follow-up.

@en

Prostate-cancer mortality at 11 years of follow-up.

@nl

P1433

Q34261229-E80F3397-FA2F-4B65-A17E-71F16E0341F9

P1476

Q34261229-44D01B19-0075-4747-9145-5630763223A2

P2093

Q34261229-0243B8A9-D796-43E2-A7FC-E09F2966AFDF

Q34261229-112F7B77-C18E-4AB5-9EFA-9D6291A0480E

Q34261229-1448C547-C1E3-4089-B682-76F1D1951305

Q34261229-15998AE8-7B97-4FC4-99C1-EC228F15D724

Q34261229-15A212DE-D25B-4B3C-B253-C0ADBC0EA773

Q34261229-16DE8B27-FCA2-4637-BE58-18446AD78A16

Q34261229-21D63BF8-379E-4411-8EF8-0F6588B1D581

Q34261229-2982B568-28A6-4419-936A-3BA932AAB2B4

Q34261229-2A2D82D8-CE01-448C-858E-5520D3578DEF

Q34261229-2FD5477A-5397-4682-BE19-E4C1EA6CA8C7

P2860

Q34261229-040E164A-3493-4AAE-B8A7-4CEDD25C0D8F

Q34261229-07993A8B-26EA-4D48-8BCF-5AEBCF1BE8B1

Q34261229-186704C7-004C-49E4-BF95-C0195630CEF2

Q34261229-2A4A6596-72C8-487E-95F4-3F07C12A32AE

Q34261229-344A4A08-7E48-4B5B-8B5F-A571F58D9625

Q34261229-35A19D49-21E1-496A-9EC4-234873DD9011

Q34261229-38E7175D-5C1D-4E5C-B20F-04CF07C8235D

Q34261229-441C3190-7CD4-4FC6-8236-E89A6230E77A

Q34261229-4E49EDD1-AB20-4DE1-A9B4-6C078CF699D3

Q34261229-59AE56D7-CB4C-47C7-99DB-BE7E378576A1

P304

Q34261229-3091D06E-C234-4C63-8350-C633B8704211

P31

Q34261229-D49AF1AB-D755-496E-AB92-8C654623B586

P356

Q34261229-2D743854-973B-45C5-A2A5-38EA7EE30D3E

P407

Q34261229-E3123E52-57B7-46F6-AB1E-77027A72B27A

P433

Q34261229-BDF3EA32-FF0A-418A-AC02-85258170EC45

P478

Q34261229-6C57D0EF-2B3F-40B4-BD0F-7F74B50FD392

P50

Q34261229-1258804F-8DBA-4AC7-8CED-9B194B25E3C7

Q34261229-2F128CB0-0F02-4B10-B303-69D6397293C7

Q34261229-89229B0B-DF8C-4E04-B588-0C29A1F9D283

Q34261229-94AE6344-EBB9-471A-A9B4-079D3E99AC86

Q34261229-F9094788-FB08-4419-A3EC-D63BDE05B04A

P577

Q34261229-856EC49D-6C98-48A8-9FAB-FEC517D86D49

P698

Q34261229-DB03B676-A850-4A29-A39E-324E67B12072

P932

Q34261229-0ACF6B5F-79EA-4926-A5F0-579CD14F527F

P356

P1433

The New England Journal of Medicine

P1476

Prostate-cancer mortality at 11 years of follow-up.

@en

P2093

Alvaro Páez

http://www.w3.org/2001/XMLSchema#string

Andreas Huber

http://www.w3.org/2001/XMLSchema#string

Bert G Blijenberg

http://www.w3.org/2001/XMLSchema#string

Chris H Bangma

http://www.w3.org/2001/XMLSchema#string

ERSPC Investigators

http://www.w3.org/2001/XMLSchema#string

Franz Recker

http://www.w3.org/2001/XMLSchema#string

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Gunnar Aus

http://www.w3.org/2001/XMLSchema#string

Harry J de Koning

http://www.w3.org/2001/XMLSchema#string

Jonas Hugosson

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

Screening and prostate-cancer mortality in a randomized European study

Number needed to screen: development of a statistic for disease screening.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

Complications after prostate biopsy: data from SEER-Medicare.

What is the true number needed to screen and treat to save a life with prostate-specific antigen testing?

Making the most out of six systematic sextant biopsies.

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.

Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.

P304

981-990

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1113135

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

Arnauld Villers

Theodorus H Van der Kwast

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22417251

http://www.w3.org/2001/XMLSchema#string

P932

6027585

http://www.w3.org/2001/XMLSchema#string